In Vivo and In Vitro Efficacy of Enhertu in Uterine Serous Carcinoma (047)

Levent Mutlu,Diego Manavella,Stefania Bellone,Justin Harold,Dennis Mauricio,Joan Tymon-Rosario,Eric Siegel,Tobias Hartwich,Gary Altwerger,Gulden Menderes,Elena Ratner,Gloria Huang,Mitchell Clark,Vaagn Andikyan,Masoud Azodi,Peter Schwartz,Alessandro Santin

DOI: https://doi.org/10.1016/s0090-8258(22)01266-5

IF: 5.304

2022-08-01

Gynecologic Oncology

Abstract:Objectives: Uterine serous carcinoma (USC) is an aggressive subtype of epithelial endometrial cancer, comprising approximately 40% of endometrial cancer-related deaths. HER2 overexpression is detected in about 35% of patients with USC. Enhertu is a novel humanized monoclonal anti-HER2 antibody (trastuzumab) linked to the topoisomerase I inhibitor payload deruxtecan by a cleavable linker. Enhertu is FDA-approved for HER2-expressing metastatic breast and gastric cancers; however, its efficacy has not been tested in endometrial cancer. The objective of this study was to study the in vitro and in vivo efficacy of Enhertu in USC. Methods: HER2 expression was analyzed with flow cytometry in primary USC cell lines: ARK2, ARK4, ARK7, and ARK20. Cell lines were treated with 0.05, 0.010, 0.025, 0.05, 0.2 μg/ml of Enhertu or Control antibody-drug conjugate (Control ADC). The inhibitory concentration 50 (IC50) was assessed by counting the viable cells using a flow cytometer. Apoptosis and necrosis were assessed with Annexin V and propidium iodide (PI) staining. GFP-expressing ARK4 (ARK4-GFP) cells were co-cultured with ARK2 cells for the bystander effect assay. For in vivo experiments, eight million ARK2 cells were injected subcutaneously into SCID mice. Animals were randomized to intravenous injection of PBS (n=5), control ADC (4 mg/kg, n=6) or Enhertu (4 mg/kg, n=5) treatment. Kruskal Wallis, Friedman, and Log Rank tests were used for statistical analysis. Results: Total 100% of ARK2 and ARK20 USC cell lines expressed HER2 by flow cytometry and had mean fluorescence intensities of 154 and 156, respectively, consistent with overexpression. Although ARK4 and ARK7 expressed HER2, their mean fluorescence intensities were 8.7 and 9.4, respectively, consistent with weak/negligible expression of HER2 in these cell lines. Enhertu mean IC50s (95% CIs) were 0.0213 (0.012-0.036) μg/ml for ARK2 and 0.0216 (0.015-0.029) μg/ml for ARK20 cell lines. On cell lines ARK4 and ARK7, no significant inhibitory effect of Enhertu was observed, and IC50 was not reached with the concentrations tested in this study. Twenty-five percent of the Control ADC and 62% of Enhertu-treated ARK2 cells became Annexin/PI double-positive apoptotic/necrotic cells by flow cytometry. Enhertu 0.050 μg/ml treatment did not exhibit cytotoxicity on ARK4-GFP cells when cultured alone; however, when co-cultured with ARK2 cells, substantial cytotoxicity on ARK4-GFP cells was observed due to the bystander effect (live cells 82% and 45% with control ADC and Enhertu, respectively). For the in vivo treatment, mean tumor volumes had day-8 means of 1.55, 1.49, and 0.7 cm3 in PBS, Control ADC, and Enhertu-treated mice, respectively (p< 0.001). Enhertu significantly improved survival compared to PBS and control ADC injected mice (p=0.002). The median survival was eight and 9.5 days for PBS and Control ADC injected mice, respectively. After 30 days of follow-up, 80% of the Enhertu injected mice were alive, and median survival was not reached. No significant weight change and toxicity were observed. Fig. 1 Fig. 2 Fig. 3 Conclusions: Enhertu showed significant preclinical efficacy against HER2 overexpressing uterine serous carcinoma cell lines. Further clinical trials in USC are warranted.

oncology,obstetrics & gynecology